MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 - Germany

This page is part of the MII IG Kerndatensatz-Modul Onkologie (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

: mii-exa-onko-tumorkonferenz-molekular

Raw json | Download

{
  "resourceType" : "CarePlan",
  "id" : "mii-exa-onko-tumorkonferenz-molekular",
  "meta" : {
    "profile" : [
      🔗 "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/StructureDefinition/mii-pr-onko-tumorkonferenz|2027.0.0-ballot.1"
    ]
  },
  "language" : "en",
  "text" : {
    "status" : "generated",
    "div" : "<div xml:lang=\"en\" lang=\"en\"><hr/><p><b>English</b></p><hr/><p class=\"res-header-id\"><b>Generated Narrative: CarePlan mii-exa-onko-tumorkonferenz-molekular</b></p><a name=\"mii-exa-onko-tumorkonferenz-molekular\"> </a><a name=\"hcmii-exa-onko-tumorkonferenz-molekular\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-mii-pr-onko-tumorkonferenz.html\">MII PR Onkologie Tumorkonferenz</a> version: 2027.0.0-ballot.1</p></div><p><b>status</b>: Active</p><p><b>intent</b>: Plan</p><p><b>category</b>: <span title=\"Codes:{https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapieplanung-typ praeth}\">Molekulares Tumorboard</span></p><p><b>subject</b>: <a href=\"Patient-example.html\">Erika Beispiel  Female, DoB: 1965-04-12</a></p><p><b>created</b>: 2024-01-15</p><p><b>addresses</b>: <a href=\"Condition-primaertumor-example.html\">Condition Bösartige Neubildung: Brustdrüse, nicht näher bezeichnet</a></p><blockquote><p><b>activity</b></p><h3>Details</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Status</b></td><td><b>Description</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapie-typ ZS}\">Zielgerichtete Anti-HER2 Therapie</span></td><td>Not Started</td><td>Basierend auf HER2-Amplifikation: Trastuzumab + Pertuzumab Kombination empfohlen</td></tr></table></blockquote><blockquote><p><b>activity</b></p><h3>Details</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Status</b></td><td><b>Description</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapie-typ CZ}\">Chemotherapie + CDK4/6 Inhibitor</span></td><td>Not Started</td><td>Alternative basierend auf HR+/HER2- Status: Palbociclib + Letrozol</td></tr></table></blockquote><blockquote><p><b>activity</b></p><h3>Details</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Status</b></td><td><b>Description</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapie-typ ST}\">Strahlentherapie</span></td><td>Not Started</td><td>Adjuvante Bestrahlung nach Operation</td></tr></table></blockquote></div>"
  },
  "status" : "active",
  "intent" : "plan",
  "category" : [
    {
      "coding" : [
        {
          "system" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapieplanung-typ",
          "code" : "praeth"
        }
      ],
      "text" : "Molekulares Tumorboard"
    }
  ],
  "subject" : {
    🔗 "reference" : "Patient/example"
  },
  "created" : "2024-01-15",
  "addresses" : [
    {
      🔗 "reference" : "Condition/primaertumor-example"
    }
  ],
  "activity" : [
    {
      "detail" : {
        "code" : {
          "coding" : [
            {
              "system" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapie-typ",
              "code" : "ZS"
            }
          ],
          "text" : "Zielgerichtete Anti-HER2 Therapie"
        },
        "status" : "not-started",
        "description" : "Basierend auf HER2-Amplifikation: Trastuzumab + Pertuzumab Kombination empfohlen"
      }
    },
    {
      "detail" : {
        "code" : {
          "coding" : [
            {
              "system" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapie-typ",
              "code" : "CZ"
            }
          ],
          "text" : "Chemotherapie + CDK4/6 Inhibitor"
        },
        "status" : "not-started",
        "description" : "Alternative basierend auf HR+/HER2- Status: Palbociclib + Letrozol"
      }
    },
    {
      "detail" : {
        "code" : {
          "coding" : [
            {
              "system" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapie-typ",
              "code" : "ST"
            }
          ],
          "text" : "Strahlentherapie"
        },
        "status" : "not-started",
        "description" : "Adjuvante Bestrahlung nach Operation"
      }
    }
  ]
}